<?xml version="1.0" encoding="UTF-8"?>
<ref id="B32-biomolecules-09-00138" class="ref">
 <label class="label">32.</label>
 <element-citation publication-type="journal" class="element-citation">
  <person-group person-group-type="author" class="person-group">
   <name class="name">
    <surname class="surname">Nagai</surname>
    <given-names class="given-names">N.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Ogata</surname>
    <given-names class="given-names">F.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Otake</surname>
    <given-names class="given-names">H.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Nakazawa</surname>
    <given-names class="given-names">Y.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Kawasaki</surname>
    <given-names class="given-names">N.</given-names>
   </name>
  </person-group>
  <article-title class="article-title">Design of a transdermal formulation containing raloxifene nanoparticles for osteoporosis treatment</article-title>
  <source class="source">Int. J. Nanomed.</source>
  <year class="year">2018</year>
  <volume class="volume">13</volume>
  <fpage class="fpage">5215</fpage>
  <lpage class="lpage">5229</lpage>
  <pub-id pub-id-type="doi" class="pub-id">10.2147/IJN.S173216</pub-id>
 </element-citation>
</ref>
